Latest Commercialization News

Zoono Group Limited reports strong progress in its shelf-life extension technology trials across multiple continents, with successful UK supermarket trials paving the way for a national roll-out in FY26. Despite a quarterly operating cash outflow, the company expects improved sales and sufficient funding to meet its near-term objectives.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Aldoro Resources has reported significant assay results from its Kameelburg project in Namibia, confirming a large polymetallic deposit rich in rare earth elements, niobium, and molybdenum. The discovery, characterized by extensive mineralization and strategic metal zonation, is shaping up as a potential Tier 1 resource with strong commercial appeal.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

Jade Gas Holdings has successfully drilled two production wells at Mongolia’s Red Lake gas field, confirming significant coal bed methane potential and preparing for imminent production. The company is advancing commercialisation talks with CNG manufacturers to capitalise on early gas flows.

AnteoTech Ltd reports progress in advanced battery and life sciences technologies alongside a strategic review and leadership changes amid challenging EV market conditions.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Hartshead Resources has submitted a revised development plan for its Anning and Somerville gas fields, featuring a superior export route via CalEnergy's Saturn Banks pipeline. Supported by a strong cash position and committed partners, the company is exploring innovative funding to optimise project economics.

Galan Lithium has locked in a binding funding and offtake agreement with Authium Limited for its Hombre Muerto West project, significantly reducing capital and operating costs. The company raised approximately A$13 million via placement and plans further shareholder funding, aiming for lithium chloride production in H1 2026.

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.

Red Sky Energy reports steady cash flow from its Innamincka Dome projects and advances development at Killanoola, while securing a significant 35% stake in offshore Angola’s Block 6/24 with promising oil resource estimates.